Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

Merck & Co has announced results from the Phase III KEYNOTE-689 trial of Keytruda (pembrolizumab) as a perioperative ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...